Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.
2.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
3.

Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Ritchie C, Smailagic N, Noel-Storr AH, Takwoingi Y, Flicker L, Mason SE, McShane R.

Cochrane Database Syst Rev. 2014 Jun 10;(6):CD008782. doi: 10.1002/14651858.CD008782.pub4. Review.

PMID:
24913723
4.

Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.

Valcárcel-Nazco C, Perestelo-Pérez L, Molinuevo JL, Mar J, Castilla I, Serrano-Aguilar P.

J Alzheimers Dis. 2014;42(3):777-88. doi: 10.3233/JAD-132216.

PMID:
24916543
5.

Biomarker modeling of Alzheimer's disease.

Jack CR Jr, Holtzman DM.

Neuron. 2013 Dec 18;80(6):1347-58. doi: 10.1016/j.neuron.2013.12.003. Review.

6.

Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.

Schneider LS, Kennedy RE, Cutter GR; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 Sep;6(5):367-77. doi: 10.1016/j.jalz.2010.07.004.

7.

The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.

Koppara A, Wolfsgruber S, Kleineidam L, Schmidtke K, Frölich L, Kurz A, Schulz S, Hampel H, Heuser I, Peters O, Reischies FM, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, Pantel J, Rienhoff O, Rüther E, Henn F, Wiltfang J, Maier W, Jessen F, Kornhuber J, Wagner M.

J Alzheimers Dis. 2016;49(2):547-60. doi: 10.3233/JAD-150257.

PMID:
26484902
8.

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.

Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR Jr, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2014 Jan 4;4:461-72. doi: 10.1016/j.nicl.2013.12.012. eCollection 2014.

9.

YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.

Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM.

Biol Psychiatry. 2010 Nov 15;68(10):903-12. doi: 10.1016/j.biopsych.2010.08.025. Erratum in: Biol Psychiatry. 2011 Feb 15;69(4):389.

10.

Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.

Höglund K, Fourier A, Perret-Liaudet A, Zetterberg H, Blennow K, Portelius E.

Clin Chim Acta. 2015 Sep 20;449:3-8. doi: 10.1016/j.cca.2015.01.041. Epub 2015 Feb 7. Review.

PMID:
25668231
11.

Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer's disease.

Zhou B, Teramukai S, Yoshimura K, Fukushima M.

J Alzheimers Dis. 2009;18(1):89-102. doi: 10.3233/JAD-2009-1124.

PMID:
19542628
12.

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR Jr, Jagust W, Toga AW, Lee VM, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2010 May;6(3):230-8. doi: 10.1016/j.jalz.2010.03.008. Review.

13.

Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.

Huded CB, Bharath S, Chandra SR, Sivakumar PT, Varghese M, Subramanian S.

Asian J Psychiatr. 2015 Feb;13:44-7. doi: 10.1016/j.ajp.2014.10.007. Epub 2014 Nov 6.

PMID:
25468261
14.

Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.

Guhra M, Thomas C, Boedeker S, Kreisel S, Driessen M, Beblo T, Ohrmann P, Toepper M.

Exp Gerontol. 2016 Jan;73:107-13. doi: 10.1016/j.exger.2015.11.008. Epub 2015 Nov 14.

PMID:
26585048
15.

Biomarkers in Alzheimer's disease: not yet surrogate endpoints.

Coley N, Andrieu S, Delrieu J, Voisin T, Vellas B.

Ann N Y Acad Sci. 2009 Oct;1180:119-24. doi: 10.1111/j.1749-6632.2009.04947.x.

PMID:
19906266
16.

Biomarkers in translational research of Alzheimer's disease.

Tarawneh R, Holtzman DM.

Neuropharmacology. 2010 Sep-Oct;59(4-5):310-22. doi: 10.1016/j.neuropharm.2010.04.006. Epub 2010 Apr 13. Review.

17.

Evidence for ordering of Alzheimer disease biomarkers.

Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS; Alzheimer's Disease Neuroimaging Initiative.

Arch Neurol. 2011 Dec;68(12):1526-35. doi: 10.1001/archneurol.2011.183. Epub 2011 Aug 8.

18.

Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.

Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C.

J Alzheimers Dis. 2014;41(2):377-86. doi: 10.3233/JAD-131838.

PMID:
24614902
19.

CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Rosenmann H.

J Mol Neurosci. 2012 May;47(1):1-14. doi: 10.1007/s12031-011-9665-5. Epub 2011 Nov 5. Review.

PMID:
22058061
20.

Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis.

Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM.

PLoS One. 2011 Apr 19;6(4):e18850. doi: 10.1371/journal.pone.0018850.

Supplemental Content

Support Center